Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Notified -

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Notified -

Sarat Ventures Y Innovations Biotech Fund to Invest in Early-Stage Companies with a focus in Saudi Arabia and the MENA Region

Notified -

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer

Notified -

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Notified -

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France

Notified -

Pow.Bio Unveils State-of-the-Art Facility in Alameda, Expanding Biomanufacturing Capabilities to Support Demand for Continuous Fermentation

Notified -

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Notified -

AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer

Notified -

Winners in First Annual Stevie® Awards for Technology Excellence Announced

Olon Group Announces the Acquisition of GTP Bioways Group

Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=f83bbfc7-6e0b-45d2-9685-2